Analysis of the Value and Safety of Anlotinib in the Treatment of Patients with Advanced Lung Cancer
Objective To explore the value and safety of anlotinib in the treatment of advanced lung cancer.Methods From December 2021 to April 2023,sixty patients with advanced lung cancer admitted to Chaohu Hospital of Anhui Medical University were non-randomly selected as the research objects and divided into two groups according to dif-ferent treatment plans,thirty cases in each group.The control group was treated with first-line chemotherapy alone,and the observation group was treated with anlotinib on the basis of the control group.The clinical efficacy,incidence of adverse reactions,quality of life,life cycle and tumor marker levels were compared between the two groups.Results The remission rate of the observation group was 73.33%(22/30),which was higher than 40.00%(12/30)of the control group,and the difference was statistically significant(χ2=6.787,P<0.05).The incidence of adverse reactions in the ob-servation group was 20.00%(6/30),which was higher than 16.67%(5/30)in the control group,but the difference was not statistically significant(χ2=0.111,P>0.05).After treatment,the quality of life,life cycle and tumor marker levels in the observation group were better than those in the control group,and the differences were statistically significant(all P<0.05).Conclusion Anlotinib is safe and effective in the treatment of patients with advanced lung cancer.It can reduce the level of tumor markers and prolong the life cycle of patients.
NETL
NSTL
万方数据
